Market Overview

Morgan Stanley Downgrades Bristol-Myers On Valuation

Related BMY
The Top 10 Value Stocks In The S&P 500
Key Takeaways From The J.P. Morgan Healthcare Conference
Ionis Pharmaceuticals Is Poised To Disrupt Biotech (Seeking Alpha)

In a note out Thursday, analyst David Risinger of Morgan Stanley lowered his rating on Bristol-Myers Squibb Co (NYSE: BMY) from Overweight to Equal-Weight, but maintained his $60 price objective.

The change is attributed to the recent rally in the shares, with Bristol-Myers having rallied 17 percent since October 2. With the stock now trading just below the $60 price target (it closed Wednesday at $58.61), he feels an Equal-weight rating is now appropriate.

Morgan Stanley's Investment Thesis:

  • We expect rising pipeline enthusiasm to drive stock outperformance.
  • BMY should trade at a significant premium to group P/E due to strong pipeline.
  • BMY stock is likely to be volatile (positive/negative) on immuno-oncology (nivo, or PD-1) newsflow.

Shares were trading slightly lower in the premarket at $58.30, down 0.53 percent.

Latest Ratings for BMY

Oct 2017Credit SuisseMaintainsNeutral
Oct 2017Leerink SwannMaintainsOutperform
Oct 2017CitigroupMaintainsBuy

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: David Risinger Morgan StanleyAnalyst Color Downgrades Analyst Ratings


Related Articles (BMY)

View Comments and Join the Discussion!